TREATMENT OF MULTIPLE MYELOMA PATIENTS WITH TANDEMAUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION IN SLOVENIJA
AbstractBACKGROUND Multiple myeloma (MM) is an incurable disease and autologous hematopoetic stem celltransplantation (HSCT) is the most effective treatment modality. It’s effectivity is evenhigher, when we treat patients with two consecutive autologous HSCT. We present ourexperiences with tandem autologous HSCT in patients with MM. METHODS During the period from 1. 1. 2003 untill 1. 11. 2007 we treated 62 MM patients. After induction therapy and stem cell collection we performed tandem autologous HSCT withinsix-month period. Treatment results were followed with biochemical parameters, monoclonal globulin peak and free light chains in serum. RESULTS Complete remission after induction was achieved in 1/62 (1,6 %) patients, after first HSCTin 6/62 (9.6 %) and after second HSCT in 24/62 (39 %) patients. Putting together CR andPR (partial remission) at three treatment steps, this was achieved in 32/62 (51 %), 51/62(82 %) and 55/62 (89 %) patients. 1/62 (1.6 %) patients died during the treatment. Meantime until relaps was 31,4 months (24.7–38.2 months; 95 % confidence interval) and forsurvival 50,2 months (44.0–56.4 months; 95 % confidence interval). Median relaps timewas 23 months (5.6–40.4 months; 95 % confidence interval), and median time for survival was not reached yet. CONCLUSIONS Treatment of MM patients with tandem autologous HSCT is highly effective treatment modality and our center’s experiences/results are comparable with other transplant centersworldwide. But in Slovenija, we must strictly perform all HSCT related investigations aswell as improve reporting all treatment related data to transplant center
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.